Virax Biolabs Group (VRAX) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts1

Ratings

Updated Sep 12, 2026

Overall Rating

B

DCF Score5.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score5.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.67

Median Target-62.55%

$1.00

Potential downside vs current price

DCF Value+437.68%

$14.36

Potential upside vs current price

Current Stock Price

$2.67

Median Target-62.55%

$1.00

Potential downside vs current price

DCF Value+437.68%

$14.36

Potential upside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts1

Ratings

Updated Sep 12, 2026

Overall Rating

B

DCF Score5.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score5.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.67

Median Target-62.55%

$1.00

Potential downside vs current price

DCF Value+437.68%

$14.36

Potential upside vs current price

Current Stock Price

$2.67

Median Target-62.55%

$1.00

Potential downside vs current price

DCF Value+437.68%

$14.36

Potential upside vs current price

Virax Biolabs Group Limited